Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 825-835

  Ollendorf, Daniel A ^a   Klingman, David ^a   Hazard, Elisabeth ^a   Ray, Saurabh ^b  

^a IQVIA   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

adalimumab; cost impact; dosage increase; etanercept; infliximab; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL COST; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; REIMBURSEMENT; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PHARMACEUTICAL SERVICES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65549157439     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.002     Document Type: Article

References (32)

1. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41 (1998) 778-799
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 46 (2002) 328-346
3. Donahue K.E., Gartlehner G., Jonas D.E., et al. Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 148 (2008) 124-134
4. Bathon J.M., Fleischmann R.M., Van der Heijde D., et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 33 (2006) 234-243
5. Kremer J.M., Weinblatt M.E., Bankhurst A.D., et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations. Arthritis Rheum. 48 (2003) 1493-1499
6. Fleischmann R.M., Cohen S.B., Moreland L.W., et al., the iRAMT Study Group. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin. 21 (2005) 1181-1190
7. St Clair E.W., van der Heijde D.M., Smolen J.S., et al., the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum. 50 (2004) 3432-3443
8. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al., the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 343 (2000) 1594-1602
9. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 65 (2006) 753-759
10. Weisman M.H., Moreland L.W., Furst D.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin Ther. 25 (2003) 1700-1721
11. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial [published correction appears in Arthritis Rheum. 2003;48:855]. Arthritis Rheum. 48 (2003) 35-45
12. Humira [package insert] (2008), Abbott Laboratories, Abbott Park, Ill
13. Enbrel [package insert] (2008), Amgen Inc, Thousand Oaks, Calif and College-ville, Pa: Wyeth Pharmaceuticals
14. Remicade [package insert] (2007), Centocor, Inc, Malvern, Pa
15. Chen Y.F., Jobanputra P., Barton P., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 10 (2006) iii-iv
16. Chen Y.F., Jobanputra P., Barton P., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 10 (2006) xi-xiii
17. Chen Y.F., Jobanputra P., Barton P., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 10 (2006) 1-229
18. Doan Q.V., Chiou C.F., and Dubois R.W. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 12 (2006) 555-569
19. Spalding J.R., and Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmaco Economics. 24 (2006) 1221-1232
20. Agarwal S.K., Maier A.L., Chibnik L.B., et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum. 53 (2005) 872-878
21. Etemad L., Yu E.B., and Wanke L.A. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface. 18 (2005) 21-27
22. Ollendorf D.A., Massarotti E., Birbara C., and Burgess S.M. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm. 11 (2005) 383-393
23. Stern R., and Wolfe F. Infliximab dose and clinical status: Results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol. 31 (2004) 1538-1545
24. Wu E., Chen L., Birnbaum H., et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 24 (2008) 2229-2240
25. Gilbert T.D., Smith D., and Ollendorf D.A. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: A retrospective cohort study. BMC Musculoskelet Disord. 5 (2004) 36
26. Finckh A., Simard J.F., Gabay C., Guerne P.A., and the SCQM Physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 65 (2006) 746-752
27. Wu E., Chen L., Birnbaum H., et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin. 23 (2007) 1749-1759
28. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40 (1987) 373-383
29. US Dept of Labor, and US Bureau of Labor Statistics. Consumer Price Index (2008). http://www.bls.gov/cpi/home.htm Accessed February 19, 2008
30. Dobson A.J., and Barnett A.G. An Introduction to Generalized Linear Models. 3rd ed. (2008), CRC Press, Boca Raton, Fla
31. Heckman J.J., Ichimura H., Smith J., and Todd P. Sources of selection bias in evaluating social programs: An interpretation of conventional measures and evidence on the effectiveness of matching as a program evaluation method. Proc Natl Acad Sci U S A. 93 (1996) 13416-13420
32. Bullano M.F., McNeeley B.J., Yu Y.F., et al. Comparison of costs associated with the use of etanercept, inflixi-mab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface. 19 (2006) 47-53